UNIGE

SINGING MACHINE ANNOUNCES NEW CARE-EOKE™ INITIATIVE AND SOCIAL GOOD MISSION ON NATIONAL SING-OUT DAY

Retrieved on: 
목요일, 5월 25, 2023
Music, The Singing Machine Company, Singing, University, Learning Unlimited, Autism spectrum, Grey, Anxiety, Workplace, Ageing, Brain, Research, University of Geneva, UNIGE, Health, Patient, Sesame Workshop, Learning, Chronic pain, Mental health, CLU, Nursing, Entertainment, Mental

Fort Lauderdale, FL, May 25, 2023 (GLOBE NEWSWIRE) -- The Singing Machine Company, Inc. (“Singing Machine” or the “Company”) (NASDAQ: MICS), the North American leader in consumer karaoke products, today announced the Company’s new CARE-eokeTM by Singing Machine initiative, and a strategic focus on social impact for children and adults of all ages who would benefit from singing. Singing Machine intends to form a series of collaborative partnerships, to help amplify the diverse emotional and physical health and wellness benefits of karaoke, beginning with formalizing its CARE-eoke by Singing Machine initiative.

Key Points: 
  • Singing Machine intends to form a series of collaborative partnerships, to help amplify the diverse emotional and physical health and wellness benefits of karaoke, beginning with formalizing its CARE-eoke by Singing Machine initiative.
  • Many health sources are reporting that singing has countless health advantages and is not just a fun pastime.
  • Rosenberg is formalizing the new CARE-eoke by Singing Machine social entrepreneurship efforts, which include working to align a series of best-in-class strategic partnerships, creating experiences and social impact storytelling to diverse audiences and stakeholders.
  • “For over four decades Singing Machine has been bringing joy through music to millions of families around the world.

MPC Therapeutics Announces Completion of Its CHF 1.5M Seed-Funding Round to Improve CAR-T Cancer Therapies.

Retrieved on: 
수요일, 1월 11, 2023
Oncology, Health, Clinical Trials, Research, Science, Biotechnology, Rejuvenation, University, Therapy, Mitochondrial pyruvate carrier 2, CHF, UNIGE, Martin Körbling, MPC, Hair, Degenerative disease, Survival, Patient, Metabolism, Cancer, University of Geneva, Pharmaceutical industry, Vaccine

MPC Therapeutics (MPC Tx), a Swiss biotechnology company focused on metabolism and rejuvenation, today announced the closing of its CHF 1.5 million seed-funding round.

Key Points: 
  • MPC Therapeutics (MPC Tx), a Swiss biotechnology company focused on metabolism and rejuvenation, today announced the closing of its CHF 1.5 million seed-funding round.
  • The funding round was led by Plutus Investment Group, a London-based family office, and received additional funding from business angels.
  • MPC Therapeutics spun-off from University of Geneva (UNIGE) in 2018 to develop molecules able to modulate mitochondrial function and trigger cellular re-programming to fight cancer and degenerative diseases.
  • MPC Therapeutics have world-class expertise and can become a leading biotech in the rapidly-growing cell therapies and cell rejuvenation markets.”